Literature DB >> 12764069

Glatiramer acetate treatment in Devic's neuromyelitis optica.

Roberto Bergamaschi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12764069     DOI： 10.1093/brain/awg140

Source DB:  PubMed          Journal:  Brain        ISSN： 0006-8950            Impact factor:   13.501


× No keyword cloud information.
  6 in total

1.  Immune agents for the treatment of Devic's neuromyelitis optica.

Authors:  R Bergamaschi
Journal:  Neurol Sci       Date:  2007-10       Impact factor: 3.307

2.  [Diagnosis and treatment of neuromyelitis optica. Consensus recommendations of the Neuromyelitis Optica Study Group].

Authors:  C Trebst; A Berthele; S Jarius; T Kümpfel; S Schippling; B Wildemann; C Wilke
Journal:  Nervenarzt       Date:  2011-06       Impact factor: 1.214

3.  Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study.

Authors:  Ilya Ayzenberg; Joanna Schöllhammer; Robert Hoepner; Kerstin Hellwig; Marius Ringelstein; Orhan Aktas; Tania Kümpfel; Markus Krumbholz; Corinna Trebst; Friedemann Paul; Florence Pache; Mark Obermann; Lena Zeltner; Matthias Schwab; Achim Berthele; Sven Jarius; Ingo Kleiter
Journal:  J Neurol       Date:  2016-01-25       Impact factor: 4.849

Review 4.  [Neuromyelitis optica].

Authors:  S Jarius; B Wildemann
Journal:  Nervenarzt       Date:  2007-12       Impact factor: 1.214

Review 5.  Molecular pathogenesis of neuromyelitis optica.

Authors:  Wajih Bukhari; Michael H Barnett; Kerri Prain; Simon A Broadley
Journal:  Int J Mol Sci       Date:  2012-10-11       Impact factor: 5.923

6.  Glatiramer acetate immune modulates B-cell antigen presentation in treatment of MS.

Authors:  Darius Häusler; Zivar Hajiyeva; Jan W Traub; Scott S Zamvil; Patrice H Lalive; Wolfgang Brück; Martin S Weber
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-03-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.